Porphyria Classification and external resources ICD-10 E80.0-E80.2 ICD-9 277.1 MedlinePlus 001208 MeSH C17.800.849.617
Porphyrias are a group of inherited or acquired disorders of certain enzymes in the heme bio-synthetic pathway (also called porphyrin pathway). They are broadly classified as acute (hepatic) porphyrias and cutaneous (erythropoietic) porphyrias, based on the site of the overproduction and accumulation of the porphyrins (or their chemical precursors). They manifest with either neurological complications or skin problems (or occasionally both). A clinically induced and histologically identical condition is called pseudoporphyria. Pseudoporphyria is characterized by normal serum and urine porphyrin levels.
The term derives from the Greek πορφύρα, porphyra, meaning "purple pigment". The name is likely to have been a reference to the purple discolouration of feces and urine in patients during an attack. Although original descriptions are attributed to Hippocrates, the disease was first explained biochemically by Felix Hoppe-Seyler in 1871, and acute porphyrias were described by the Dutch physician Barend Stokvis in 1889.
The prevalence of all types of porphyria taken together has been estimated to be approximately 1 in 25,000 in the United States. The worldwide prevalence has been estimated to be somewhere between 1 in 500 to 1 in 50,000 people.
- 1 Signs and symptoms
- 2 Diagnosis
- 3 Pathogenesis
- 4 Treatment
- 5 Culture and history
- 6 Notable cases
- 7 References
- 8 External links
Signs and symptoms
The acute, or hepatic, porphyrias primarily affect the nervous system, resulting in abdominal pain, vomiting, acute neuropathy, muscle weakness, seizures, and mental disturbances, including hallucinations, depression, anxiety, and paranoia. Cardiac arrhythmias and tachycardia (high heart rate) may develop as the autonomic nervous system is affected. Pain can be severe and can, in some cases, be both acute and chronic in nature. Constipation is frequently present, as the nervous system of the gut is affected, but diarrhea can also occur.
Given the many presentations and the relatively low occurrence of porphyria, the patient may initially be suspected to have other, unrelated conditions. For instance, the polyneuropathy of acute porphyria may be mistaken for Guillain-Barré syndrome, and porphyria testing is commonly recommended in those situations. Systemic lupus erythematosus features photosensitivity and pain attacks and shares various other symptoms with porphyria.
Not all porphyrias are genetic, and patients with liver disease who develop porphyria as a result of liver dysfunction may exhibit other signs of their condition, such as jaundice.
Patients with acute porphyria (AIP, HCP, VP) are at increased risk over their life for hepatocellular carcinoma (primary liver cancer) and may require monitoring. Other typical risk factors for liver cancer need not be present.
The cutaneous, or erythropoietic, porphyrias primarily affect the skin, causing photosensitivity (photodermatitis), blisters, necrosis of the skin and gums, itching, and swelling, and increased hair growth on areas such as the forehead. Often there is no abdominal pain, distinguishing it from other porphyrias.
In some forms of porphyria, accumulated heme precursors excreted in the urine may cause various changes in color, after exposure to sunlight, to a dark reddish or dark brown color. Even a purple hue or red urine may be seen.
Porphyria is diagnosed through spectroscopy and biochemical analysis of blood, urine, and stool. In general, urine estimation of porphobilinogen (PBG) is the first step if acute porphyria is suspected. As a result of feedback, the decreased production of heme leads to increased production of precursors, PBG being one of the first substances in the porphyrin synthesis pathway. In nearly all cases of acute porphyria syndromes, urinary PBG is markedly elevated except for the very rare ALA dehydratase deficiency or in patients with symptoms due to hereditary tyrosinemia type I. In cases of mercury- or arsenic poisoning-induced porphyria, other changes in porphyrin profiles appear, most notably elevations of uroporphyrins I & III, coproporphyrins I & III and pre-coproporphyrin.
Repeat testing during an attack and subsequent attacks may be necessary in order to detect a porphyria, as levels may be normal or near-normal between attacks. The urine screening test has been known to fail in the initial stages of a severe life threatening attack of acute intermittent porphyria.
The bulk (up to 90%) of the genetic carriers of the more common, dominantly inherited acute hepatic porphyrias (acute intermittent porphyria, hereditary coproporphyria, variegate porphyria) have been noted in DNA tests to be latent for classic symptoms and may require DNA or enzyme testing. The exception to this may be latent post-puberty genetic carriers of hereditary coproporphyria.
As most porphyrias are rare conditions, general hospital labs typically do not have the expertise, technology or staff time to perform porphyria testing. In general, testing involves sending samples of blood, stool and urine to a reference laboratory. All samples to detect porphyrins must be handled properly. Samples should be taken during an acute attack, otherwise a false negative result may occur. Samples must be protected from light and either refrigerated or preserved.
Further diagnostic tests of affected organs may be required, such as nerve conduction studies for neuropathy or an ultrasound of the liver. Basic biochemical tests may assist in identifying liver disease, hepatocellular carcinoma, and other organ problems.
Deficiency in the enzymes of the porphyrin pathway leads to insufficient production of heme. Heme function plays a central role in cellular metabolism. This is not the main problem in the porphyrias; most heme synthesis enzymes—even dysfunctional enzymes—have enough residual activity to assist in heme biosynthesis. The principal problem in these deficiencies is the accumulation of porphyrins, the heme precursors, which are toxic to tissue in high concentrations. The chemical properties of these intermediates determine the location of accumulation, whether they induce photosensitivity, and whether the intermediate is excreted (in the urine or feces).
There are eight enzymes in the heme biosynthetic pathway, four of which—the first one and the last three—are in the mitochondria, while the other four are in the cytosol. Defects in any of these can lead to some form of porphyria.
The hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain and an acute polyneuropathy), while the erythropoietic forms present with skin problems, usually a light-sensitive blistering rash and increased hair growth.
Variegate porphyria (also porphyria variegata or mixed porphyria), which results from a partial deficiency in PROTO oxidase, manifests itself with skin lesions similar to those of porphyria cutanea tarda combined with acute neurologic attacks. All other porphyrias are either skin- or nerve-predominant.
Subtypes of porphyrias depend on what enzyme is deficient.
Enzyme Associated porphyria Type of porphyria Inheritance Symptoms Prevalence δ-aminolevulinate (ALA) synthase X-linked sideroblastic anemia (XLSA) Erythropoietic X-linked δ-aminolevulinate dehydratase (ALAD) Doss porphyria/ALA dehydratase deficiency Hepatic Autosomal recessive  Abdominal pain, neuropathy Extremely rare (less than 10 cases ever reported) hydroxymethylbilane (HMB) synthase (or PBG deaminase) acute intermittent porphyria (AIP) Hepatic Autosomal dominant  Periodic abdominal pain, peripheral neuropathy, psychiatric disorders, tachycardia 1 in 10,000-20,000 uroporphyrinogen (URO) synthase Congenital erythropoietic porphyria (CEP) Erythropoietic Autosomal recessive  Severe photosensitivity with erythema, swelling and blistering. Hemolytic anemia, splenomegaly 1 in 1,000,000 or less. uroporphyrinogen (URO) decarboxylase Porphyria cutanea tarda (PCT) Hepatic Autosomal dominant  Photosensitivity with vesicles and bullae 1 in 10,000 coproporphyrinogen (COPRO) oxidase Hereditary coproporphyria (HCP) Hepatic Autosomal dominant  Photosensitivity, neurologic symptoms, colic 1 in 500,000 protoporphyrinogen (PROTO) oxidase Variegate porphyria (VP) Mixed Autosomal dominant  Photosensitivity, neurologic symptoms, developmental delay 1 in 300 in South Africa
1 in 75.000 in Finland
Ferrochelatase Erythropoietic protoporphyria (EPP) Erythropoietic Autosomal dominant  Photosensitivity with skin lesions. Gallstones, mild liver dysfunction 1 in 75,000-200,000 Transient erythroporphyria of infancy Purpuric skin lesions:526
- Carbohydrates and heme
Often, empirical treatment is required if the diagnostic suspicion of a porphyria is high since acute attacks can be fatal. A high-carbohydrate diet is typically recommended; in severe attacks, a glucose 10% infusion is commenced, which may aid in recovery.
Hematin (trade name Panhematin) and heme arginate (trade name NormoSang) are the drugs of choice in acute porphyria, in the United States and the United Kingdom, respectively. These drugs need to be given very early in an attack to be effective; effectiveness varies amongst individuals. They are not curative drugs but can shorten attacks and reduce the intensity of an attack. Side effects are rare but can be serious. These heme-like substances theoretically inhibit ALA synthase and hence the accumulation of toxic precursors. In the United Kingdom, supplies of NormoSang are kept at two national centers; emergency supply is available from St Thomas' Hospital, London. In the United States, Lundbeck manufactures and supplies Panhematin for infusion.
Heme Arginate (NormoSang) is used during crises but also in preventive treatment to avoid crises, one treatment every 10 days
Any sign of low blood sodium (hyponatremia) or weakness should be treated with the addition of hematin or heme arginate or even Tin Mesoporphyrin as these are signs of impending syndrome of inappropriate antidiuretic hormone (SIADH) or peripheral nervous system involvement that may be localized or severe progressing to bulbar paresis and respiratory paralysis.
- Precipitating factors
If drugs or hormones have caused the attack, discontinuing the offending substances is essential. Infection is one of the top causes of attacks and requires vigorous treatment.
- Symptom control
Pain is severe, frequently out of proportion to physical signs and often requires the use of opiates to reduce it to tolerable levels. Pain should be treated as early as medically possible, due to its severity. Nausea can be severe; it may respond to phenothiazine drugs but is sometimes intractable. Hot water baths/showers may lessen nausea temporarily, though caution should be used to avoid burns or falls.
- Early identification
It is recommended that patients with a history of acute porphyria, and even genetic carriers, wear an alert bracelet or other identification at all times. This is in case they develop severe symptoms, or in case of accidents where there is a potential for drug exposure, and as a result they are unable to explain their condition to healthcare professionals. Some drugs are absolutely contraindicated for any patients with any porphyria.
- Neurologic and psychiatric issues
Patients who experience frequent attacks can develop chronic neuropathic pain in extremities as well as chronic pain in the gut. Gut dysmotility, ileus, intussusception, hypoganglionosis, encopresis in children and intestinal pseudo-obstruction have been associated with porphyrias. This is thought to be due to axonal nerve deterioration in affected areas of the nervous system and vagal nerve dysfunction.
In these cases treatment with long-acting opioids may be indicated. Some cases of chronic pain can be difficult to manage and may require treatment using multiple modalities. Opioid dependence may develop.
Depression often accompanies the disease and is best dealt with by treating the offending symptoms and if needed the judicious use of anti-depressants. Some psychotropic drugs are porphyrinogenic, limiting the therapeutic scope.
Seizures often accompany this disease. Most seizure medications exacerbate this condition. Treatment can be problematic: barbiturates especially must be avoided. Some benzodiazepines are safe and, when used in conjunction with newer anti-seizure medications such as gabapentin, offer a possible regime for seizure control.
Magnesium sulfate and bromides have also been used in porphyria seizures, however, development of status epilepticus in porphyria may not respond to magnesium alone. The addition of hematin or heme arginate has been used during status epilepticus.
- Underlying liver disease
Some liver diseases may cause porphyria even in the absence of genetic predisposition. These include hemochromatosis and hepatitis C. Treatment of iron overload may be required.
- Hormone treatment
Hormonal fluctuations that contribute to cyclical attacks in women have been treated with oral contraceptives and luteinizing hormones to shut down menstrual cycles. However, oral contraceptives have also triggered photosensitivity and withdrawal of oral contraceptives has triggered attacks. Androgens and fertility hormones have also triggered attacks.
These are associated with accumulation of porphyrins in erythrocytes and are rare. The rarest is Congenital erythropoetic porphyria (C.E.P) otherwise known as Gunther's disease. The signs may present from birth and include severe photosensitivity, brown teeth that fluoresce in ultraviolet light due to deposition of type one porphyrins and later hypertrichosis. Hemolytic anemia usually develops. Pharmaceutical-grade beta carotene may be used in its treatment. A bone marrow transplant has also been successful in curing CEP in a few cases, although long term results are not yet available.
The pain, burning, swelling and itching that occur in erythropoietic porphyrias generally require avoidance of bright sunlight. Most kinds of sunscreen are not effective, but SPF-rated long-sleeve shirts, hats, bandanas and gloves can help. Chloroquine may be used to increase porphyrin secretion in some EPs. Blood transfusion is occasionally used to suppress innate heme production.
Culture and history
Porphyrias have been detected in all races, multiple ethnic groups on every continent including Africans, Asians, Australian aborigines, Caucasians, Peruvian, Mexican, Native Americans, and Sami. There are high incidence reports of AIP in areas of India and Scandinavia and over 200 genetic variants of AIP, some of which are specific to families, although some strains have proven to be repeated mutations.
The links between porphyrias and mental illness have been noted for decades. In the early 1950s patients with porphyrias (occasionally referred to as "Porphyric Hemophilia") and severe symptoms of depression or catatonia were treated with electroshock.
Vampires and werewolves
In January 1964, L. Illis' 1963 paper, "On Porphyria and the Aetiology of Werwolves", was published in Proceedings of the Royal Society of Medicine. Later, Nancy Garden argued for a connection between porphyria and the vampire belief in her 1973 book, Vampires. In 1985, biochemist David Dolphin's paper for the American Association for the Advancement of Science, "Porphyria, Vampires, and Werewolves: The Aetiology of European Metamorphosis Legends", gained widespread media coverage, thus popularizing the connection.
The theory has since faced criticism, especially for the stigma it has placed on its sufferers. Norine Dresser's 1989 book American Vampires: Fans, Victims, Practitioners deals with this.
The theory also operates on a flawed premise, mainly in regard to a perceived harmful effect sunlight had on vampires, a property relatively late to vampire belief. There are about eight different types of porphyria; four of these can sometimes cause sensitivity to light: Erythropoietic Protoporphyria (EPP) or Protoporphyria, Congenital Erythropoietic Porphyria (C.E.P.), Porphyria Cutanea Tarda (PCT) and Variegate Porphyria.
The mental illness exhibited by King George III evidenced in the regency crisis of 1788 has inspired several attempts at retrospective diagnosis. The first, written in 1855, thirty-five years after his death, concluded he suffered from acute mania. M. Guttmacher, in 1941, suggested manic-depressive psychosis as a more likely diagnosis. The first suggestion that a physical illness was the cause of King George's mental derangements came in 1966, in a paper "The Insanity of King George III: A Classic Case of Porphyria", with a follow-up in 1968, "Porphyria in the Royal Houses of Stuart, Hanover and Prussia". The papers, by a mother/son psychiatrist team, were written as though the case for porphyria had been proven, but the response demonstrated that many, including those more intimately familiar with actual manifestations of porphyria, were unconvinced. Many psychiatrists disagreed with Hunter's diagnosis, suggesting bipolar disorder as far more probable. The theory is treated in Purple Secret, which documents the ultimately unsuccessful search for genetic evidence of porphyria in the remains of royals suspected to suffer from it. In 2005 it was suggested that arsenic (which is known to be porphyrogenic) given to George III with antimony may have caused his porphyria. Despite the lack of direct evidence, the notion that George III (and other members of the royal family) suffered from porphyria has achieved such popularity that many forget that it is merely a hypothesis. In 2010 an exhaustive analysis of historical records revealed that the porphyria claim was based on spurious and selective interpretation of contemporary medical and historical sources.
The mental illness of George III is the basis of the plot in The Madness of King George, a 1994 British film based upon the 1991 Alan Bennett play, The Madness of George III. The closing credits of the film include the comment that the illness suffered by King George has been attributed to porphyria and that it is hereditary. Among other descendants of George III theorised by the authors of Purple Secret to have suffered from porphyria (based upon analysis of their extensive and detailed medical correspondence) were his great-great-granddaughter Princess Charlotte of Prussia (Emperor William II's eldest sister) and her daughter Princess Feodora of Saxe-Meiningen. They had more success in being able to uncover reliable evidence that George III's great-great-great-grandson Prince William of Gloucester was reliably diagnosed with variegate porphyria.
It is believed[by whom?] that Mary, Queen of Scots – King George III's great-great-great-great-great-grandmother – also suffered from acute intermittent porphyria, although this is subject to much debate. It is assumed she inherited the disorder, if indeed she had it, from her father, James V of Scotland; both father and daughter endured well-documented attacks that some[who?] believe fall within the constellation of symptoms of porphyria.
Other commentators have suggested that Vincent van Gogh may have suffered from acute intermittent porphyria. It has also been imagined that King Nebuchadnezzar of Babylon suffered from some form of porphyria (cf. Daniel 4). However, the symptoms of the various porphyrias are so extensive that a wide constellation of symptoms can be attributed to one or more of them.
Paula Frías Allende, the daughter of the Chilean novelist Isabel Allende, fell into a porphyria-induced coma in 1991 which inspired Isabel Allende to write the autobiographical book Paula, dedicated to her daughter.
- ^ a b Nick Lane (2002-12-16). "Born to the purple: the story of porphyria". Scientific American. http://www.sciam.com/article.cfm?articleID=000B1BEF-C051-1DF8-9733809EC588EEDF. Retrieved 2008-08-05.
- ^ Hoppe-Seyler F (1871). "Das Hämatin". Tubinger Med-Chem Untersuch 4: 523–33.
- ^ Stokvis BJ. "Over twee zeldzame kleurstoffen in urine van zieken" (in Dutch). Nederl Tijdschr Geneeskd 2: 409–417. Reprinted in Stokvis BJ (December 1989). "Over twee zeldzame kleurstoffen in urine van zieken" (in Dutch). Ned Tijdschr Geneeskd 133 (51): 2562–70. PMID 2689889.
- ^ eMedicine > Porphyria, Cutaneous Authors: Vikramjit S Kanwar, Thomas G DeLoughery, Richard E Frye and Darius J Adams. Updated: Jul 27, 2010
- ^ Genetics Home Reference > Porphyria Reviewed July 2009
- ^ Albers JW, Fink JK (2004). "Porphyric neuropathy". Muscle Nerve 30 (4): 410–422. doi:10.1002/mus.20137. PMID 15372536.
- ^ Roelandts R (2000). "The diagnosis of photosensitivity". Arch Dermatol 136 (9): 1152–1157. doi:10.1001/archderm.136.9.1152. PMID 10987875.
- ^ a b c d Thadani H, Deacon A, Peters T (2000). "Diagnosis and management of porphyria". BMJ 320 (7250): 1647–1651. doi:10.1136/bmj.320.7250.1647. PMC 1127427. PMID 10856069. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1127427.
- ^ Anderson KE, Bloomer JR, Bonkovsky HL et al. (2005). "Recommendations for the diagnosis and treatment of the acute porphyrias". Ann. Intern. Med. 142 (6): 439–50. PMID 15767622.
- ^ Woods, J.S. (1995). "Porphyrin metabolism as indicator of metal exposure and toxicity". In Goyer, R.A. & Cherian, M.G.. Toxicology of metals, biochemical aspects. 115. Berlin: Springer. pp. 19–52, Chapter 2.
- ^ a b c d e f g h i j k l m Table 18-1 in: Marks, Dawn B.; Swanson, Todd; Sandra I Kim; Marc Glucksman (2007). Biochemistry and molecular biology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 0-7817-8624-X.
- ^ Overview of the Porphyrias at The Porphyrias Consortium (a part of NIH Rare Diseases Clinical Research Network (RDCRN)) Retrieved June 2011
- ^ a b Medscape > Diseases of Tetrapyrrole Metabolism - Refsum Disease and the Hepatic Porphyrias Author: Norman C Reynolds. Chief Editor: Stephen A Berman. Updated: Mar 23, 2009
- ^ Thadani, H.; Deacon, A.; Peters, T. (2000). "Diagnosis and management of porphyria". BMJ 320 (7250): 1647–1651. doi:10.1136/bmj.320.7250.1647. PMC 1127427. PMID 10856069. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1127427.
- ^ a b c d e Arceci, Robert.; Hann, Ian M.; Smith, Owen P. (2006). Pediatric hematolog. Malden, Mass.: Blackwell Pub.. ISBN 978-1-4051-3400-2.
- ^ Mustajoki, P. (1980). "Variegate porphyria. Twelve years' experience in Finland". The Quarterly journal of medicine 49 (194): 191–203. PMID 7433635.
- ^ James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- ^ "9.8.2: Acute porphyrias". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. March 2009. p. 549. ISBN 9780853698456.
- ^ American Porphyria Foundation (2010). "Panhematin for Acute Porphyria". http://www.porphyriafoundation.com/testing-and-treatment/medications-for-porphyria/panhematin. Retrieved 2010-08-05.
- ^ Martin A Crook.2006. Clinical chemistry and Metabolic Medicine. seventh edition. Hodder Arnold. ISBN 0-340-90616-2
- ^ Faraci M, Morreale G, Boeri E et al. (2008). "Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria". Pediatr Transplant 12 (1): 117–120. doi:10.1111/j.1399-3046.2007.00842.x. PMID 18186900.
- ^ Denver, Joness. "An Encyclopaedia of Obscure Medicine". Published by University Books, Inc., 1959.
- ^ One example is the comic book Ultimate Comics Avengers 3 #1 (October 2010), in which writer Mark Millar employed porphyria as the explanation for vampires in that fictional universe.
- ^ Puy H, Gouya L, Deybach JC (March 2010). "Porphyrias". Lancet 375 (9718): 924–37. doi:10.1016/S0140-6736(09)61925-5. PMID 20226990.
- ^ Macalpine I, Hunter R (January 1966). "The "insanity" of King George 3d: a classic case of porphyria". Br Med J 1 (5479): 65–71. doi:10.1136/bmj.1.5479.65. PMC 1843211. PMID 5323262. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1843211.
- ^ Macalpine I, Hunter R, Rimington C (January 1968). "Porphyria in the royal houses of Stuart, Hanover, and Prussia. A follow-up study of George 3d's illness". Br Med J 1 (5583): 7–18. doi:10.1136/bmj.1.5583.7. PMC 1984936. PMID 4866084. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1984936.
- ^ Warren, Martin; Rh̲l, John C. G.; Hunt, David C. (1998). Purple secret: genes, "madness" and the Royal houses of Europe. London: Bantam. ISBN 0-593-04148-8.
- ^ The authors demonstrated a single point mutation in the PPOX gene, but not one which has been associated with disease.
- ^ Cox TM, Jack N, Lofthouse S, Watling J, Haines J, Warren MJ (2005). "King George III and porphyria: an elemental hypothesis and investigation". Lancet 366 (9482): 332–335. doi:10.1016/S0140-6736(05)66991-7. PMID 16039338.
- ^ Peters TJ, Wilkinson D (2010). "King George III and porphyria: a clinical re-examination of the historical evidence". History of Psychiatry 21: 3–19. doi:10.1177/0957154X09102616.
- ^ Loftus LS, Arnold WN (1991). "Vincent van Gogh's illness: acute intermittent porphyria?". BMJ 303 (6817): 1589–1591. doi:10.1136/bmj.303.6817.1589. PMC 1676250. PMID 1773180. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1676250.
- ^ Beveridge A (2003). "The madness of politics". J R Soc Med 96 (12): 602–604. doi:10.1258/jrsm.96.12.602. PMC 539664. PMID 14645615. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=539664.
- American Porphyria Foundation
- European Porphyria Initiative
- The British Porphyria Association
- The Drug Database for Acute Porphyria - comprehensive database on drug porphyrinogenicity
Heme metabolism disorders (E80, 277.1, 277.4) Porphyria,
hepatic and erythropoietic
Wikimedia Foundation. 2010.
См. также в других словарях:
porphyria — porphyria. См. порфирии. (Источник: «Англо русский толковый словарь генетических терминов». Арефьев В.А., Лисовенко Л.А., Москва: Изд во ВНИРО, 1995 г.) … Молекулярная биология и генетика. Толковый словарь.
porphyria — 1923, from porphyrin (1910), from Ger. porphyrin, chemical name, from Gk. porphyros вЂњpurpleвЂќ (see PURPLE (Cf. purple)) + IN (Cf. in) (2). Some of the compounds are purple … Etymology dictionary
porphyria — [pôr fir′ē ə] n. [ModL < PORPHYRIN + IA] an inherited disorder of pigment metabolism with excretion of porphyrins in the urine and dangerous sensitivity to sunlight … English World dictionary
porphyria — /pawr fear ee euh, fuy ree euh/, n. Pathol. a defect of blood pigment metabolism in which porphyrins are produced in excess, are present in the blood, and are found in the urine. Also called hematoporphyria. [1920 25; PORPHYR(IN) + IA] * * * ▪… … Universalium
Porphyria — Any of a group of inherited diseases characterized by skin sensitivity to sunlight and/or by intermittent acute attacks of abdominal and nerve pain. The porphyrias are caused by enzyme defects that trigger the overproduction of porphyrins by the… … Medical dictionary
porphyria — n. one of a group of rare disorders due to inborn errors of metabolism in which there are deficiencies in the enzymes involved in the biosynthesis of haem. The accumulation of the enzyme s substrate gives rise to symptoms of the disorder. The… … The new mediacal dictionary
Porphyria — (Poor FEAR ee ah) Porphyria is a rare hereditary medical condition in which a person s body does not produce heme, the main component in hemoglobin. Those who suffer with this disease have a sensitivity to sunlight, allergic reactions to GARLIC,… … Encyclopedia of vampire mythology
porphyria — n. any of a group of genetic disorders associated with abnormal metabolism of various pigments. Etymology: mod.L f. porphyrin purple substance excreted by porphyria patients f. Gk porphura purple … Useful english dictionary
porphyria — noun Etymology: New Latin, from International Scientific Vocabulary porphyrin Date: 1923 any of several usually hereditary abnormalities of porphyrin metabolism characterized by excretion of excess porphyrins in the urine … New Collegiate Dictionary
porphyria — Any of a group of disorders in which there is excessive excretion of porphyrins or their precursors … Dictionary of molecular biology